|
| Press Releases |
|
 |
|
| Tuesday, March 3, 2026 |
|
|
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults. more info >> |
|
| Monday, September 29, 2025 |
|
|
Hua Medicine Announces the Pharmaceutical Service of Hong Kong Department of Health of China has Officially Accepted the Application for Marketing Authorization of the New Drug Dorzagliatin |
| Hua Medicine (HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world's first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D). more info >> |
|
| Thursday, August 28, 2025 |
|
|
Hua Medicine Announces 2025 Interim Results |
| Hua Medicine (the 'Company', HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the 'Reporting Period'), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing'(dorzagliatin tablets), accelerated. The Company's independent operational capabilities improved significantly. more info >> |
|
| Monday, June 23, 2025 |
|
|
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis |
| Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). more info >> |
|
| Friday, March 28, 2025 |
|
|
Hua Medicine Announces 2024 Annual Results |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the "Reporting Period"), along with the Company's business progress in 2024 and future business outlook. more info >> |
|
| Tuesday, March 18, 2025 |
|
|
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce |
| On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. more info >> |
|
| Monday, March 3, 2025 |
|
|
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters |
| On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. more info >> |
|
| Saturday, November 30, 2024 |
|
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia
Mar 25, 2026 20:30 HKT/SGT
|
|
|
Adyton Reports 6.60g/t Au, 2.44% Cu and 39.8g/t Ag Within 164m @ 0.82g/t AuEq Including 53m at 1.60g/t AuEq Within 164m at 0.82g/t AuEq from the Northeastern Extension Target, Feni Island
Mar 25, 2026 19:29 HKT/SGT
|
|
|
Emperor Watch & Jewellery Limited Announces 2025 Annual Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
Kingsoft announces 2025 Annual and Fourth Quarter Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
New 2026 Office Bearers Announced for CropLife Asia
Mar 25, 2026 18:00 HKT/SGT
|
|
|
IGG 'Doomsday: Last Survivors' Achieves Record-High Monthly Gross Billing of HK$130 Million
Mar 25, 2026 17:40 HKT/SGT
|
|
|
Exito Media Concepts Announces the 31st Global Edition of the Cyber Security Summit Australia 2026 
Mar 25, 2026 17:18 HKT/SGT
|
|
|
Exito Media Concepts Announces the 33rd Global Edition of the BFSI IT Summit Australia 2026
Mar 25, 2026 16:58 HKT/SGT
|
|
|
GTJAI (1788.HK) Achieved Record-High Revenue in 2025 with Profitability Making a Leapfrog Improvement
Mar 25, 2026 16:44 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 25, 2026 16:34 HKT/SGT
|
|
|
Thailand Exhibition Association Unveils Transformative MICE Masterplan 2026-2027, as the Region's Premier Innovation and Sustainability Hub, Aims to Propel TMX 2026 Beyond 4,000 Global Industry Leaders
Mar 25, 2026 16:26 HKT/SGT
|
|
|
Sumitomo Heavy Industries and NEC to develop system capable of identifying and reporting near-miss incidents
Mar 25, 2026 14:27 JST
|
|
|
NEC Orchestrating Future Fund Invests in U.S.-based AGI7, Provider of "Alpha Vision" Platform for Autonomous Operations of AI Agents in Physical Spaces
Mar 25, 2026 13:17 JST
|
|
|
TransNusa Becomes First Indonesian Airline to Receive Additional Flight Frequencies from World-Renowned Changi Airport in 2026
Mar 25, 2026 10:00 HKT/SGT
|
|
|
Fujitsu and The University of Osaka develop new technologies for chemical material energy calculations on early-FTQC quantum computers
Mar 25, 2026 10:58 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
